Try our Advanced Search for more refined results
FEDERAL TRADE COMMISSION v. ABBVIE INC et al
Case Number:
2:14-cv-05151
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
June 06, 2017
FTC, AbbVie Seek Quick Wins In Androgel Antitrust Suit
The Federal Trade Commission and a host of pharmaceutical companies on Monday filed dueling summary judgment bids in the FTC's Pennsylvania case accusing the drugmakers of filing sham patent litigation against generic rivals over its testosterone replacement treatment AndroGel, sparring over allegations that the patent litigation was objectively baseless.
-
March 27, 2017
FTC Gets Ex-Patent Atty Testimony Blocked In Androgel Suit
A Pennsylvania federal judge sided with the Federal Trade Commission in the agency's antitrust suit against AbbVie on Monday, striking an expert report and preventing the testimony of a retired Covington & Burling LLP patent attorney.
-
March 08, 2017
FTC Looks To Bar Ex-Patent Atty's Testimony In Androgel Suit
The Federal Trade Commission on Tuesday asked a Pennsylvania federal judge to strike an expert report and prevent the testimony of a retired Covington & Burling LLP patent attorney, arguing that the former partner is acting as a defense counsel from the witness stand.
-
August 25, 2016
FTC Wins Access To AndroGel Docs In AbbVie Antitrust Suit
Pharmaceutical company AbbVie must hand over to the U.S. Federal Trade Commission a trove of various documents and presentation materials that it claimed were privileged in the FTC's pay-for-delay suit over testosterone replacement treatment AndroGel because it failed to show attorney-client protections, a Pennsylvania federal judge ruled Thursday.
-
August 11, 2016
FTC Wins AndroGel Info From AbbVie In Antitrust Suit
A Pennsylvania federal judge on Thursday ordered AbbVie to hand over to the U.S. Federal Trade Commission documents from its board of directors concerning the marketing of testosterone treatment AndroGel in a pay-for-delay suit brought by the agency.
-
July 15, 2016
AbbVie Urges Judge To Nix FTC's Bid For 'Irrelevant' Info
AbbVie urged a Pennsylvania federal court on Thursday to reject a bid by the Federal Trade Commission to compel the pharmaceutical company to issue new responses to questions in a pay-for-delay suit over the testosterone treatment AndroGel, saying the government's queries have either been answered or are "irrelevant."
-
July 05, 2016
FTC Says AbbVie Must Produce Board Docs In AndroGel Fight
The Federal Trade Commission has asked a Pennsylvania federal judge to order AbbVie Inc. to release documents from its board of directors in a pay-for-delay suit over the testosterone treatment AndroGel, saying the drug company has been stalling over the request for months in a "cat and mouse game."
-
June 29, 2016
FTC Urges Pa. Judge Not To Extend Deadline For Abbvie Docs
The Federal Trade Commission on Tuesday hit back at Abbvie Inc.'s Monday assertion that the agency is bringing up "new purported discovery disputes" in a pay-for-delay suit over the testosterone treatment AndroGel, urging a Pennsylvania federal judge not to allow Abbvie to delay resolution of Abbvie's outstanding privilege challenges.
-
March 02, 2016
FTC Scores Patent-Related Docs In AndroGel Row
The Federal Trade Commission persevered in Pennsylvania federal court Tuesday on document requests from two Mayer Brown LLP attorneys and an AbbVie Inc. research scientist that the agency says are related to the patent for AndroGel at issue in a pay-for-delay suit over the testosterone treatment.
-
February 26, 2016
FTC Backs Off Some Doc Demands In Androgel Fight
The Federal Trade Commission in a filing in Pennsylvania federal court on Thursday backed off on requests that two people connected to Besins Healthcare Inc. hand over documents in the agency's pay-for-delay suit over the testosterone treatment Androgel, citing new information that recently came to light.